Evidence map›Paper›PMID 41769265›Full record

ReviewDrug design, development and therapy2026

Drug Polymer Nanoparticles: An Advancement in Biomedical Solutions and Targeted Drug Delivery.

Pranita Rananaware, Mahesh Narayan, Varsha Brahmkhatri

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Functions and mechanisms of miR-650 in human diseases.Frontiers in molecular biosciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pranita RananawareCentre for Nano and Material Sciences, Jain University, Jain Global Campus, Bengaluru, Karnataka, India.
Mahesh NarayanDepartment of Chemistry and Biochemistry, University of Texas at El Paso, El Paso, TX, 79968, USA.
Varsha BrahmkhatriCentre for Nano and Material Sciences, Jain University, Jain Global Campus, Bengaluru, Karnataka, India.ORCID 0000-0002-9650-729X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymer nanoparticles (PNPs) are compact particulate systems typically ranging from 10 to 1000 nm in size and have emerged as versatile platforms in modern biomedical research. Their growing importance stems from a unique combination of physicochemical properties, including tunable size, surface functionality, high drug loading capacity, and favourable biocompatibility. These features enable PNPs to act as efficient matrix carriers capable of encapsulating, protecting, and co-delivering a wide variety of therapeutic agents, including small molecules, proteins, and nucleic acids, within a single targeted delivery system. One of the key advantages of PNPs lies in their ability to improve both pharmacokinetic and pharmacodynamic profiles of drugs. By controlling drug release, enhancing solubility of poorly water soluble compounds, and reducing premature degradation or clearance, PNP-based systems can increase therapeutic efficacy while minimizing systemic toxicity. Targeting ligands can be incorporated on the nanoparticle surface to promote site-specific drug delivery, further improving treatment outcomes. A range of preparation techniques has been developed for the fabrication of advanced PNPs. These methods are generally classified according to the underlying particle formation mechanism, including polymerization-based approaches that generate nanoparticles directly and techniques that utilize preformed polymers. Advances in nanotechnology and polymer chemistry have enabled precise control over nanoparticle composition, morphology, and surface characteristics, leading to the development of sophisticated colloidal drug delivery systems. The integration of diverse nanomaterials into PNP formulations has further expanded their functional scope, significantly influencing the pharmacological and biopharmaceutical behavior of encapsulated drugs. Owing to their biocompatibility and design flexibility, PNPs have found broad applications in the treatment of cancer, neurodegenerative diseases, central nervous system disorders, and other complex medical conditions. This review elaborates on these aspects, highlighting the potential of PNPs as adaptable and powerful tools in next-generation therapeutic strategies.

Indexed as

Drug CarriersDrug Delivery SystemsNanoparticlesPolymersAnimalsHumansDrug CarriersPolymersdisease curedrug deliveryliposomespolymer nanoparticlestargeted therapy

Identifiers

PMID41769265
PMCPMC12949382

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.